Angion’s kidney therapy advances
The 28-patient study showed that Angion’s drug improved kidney function, based on patients’ estimated glomerular filtration rate (eGFR), a key renal function metric.
Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock
Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ) said Friday they eradicated nearly all traces of hepatitis B virus in a Phase 2 study — sending Arrowhead stock careening toward a record high. On the stock market today, Arrowhead stock jumped 6.3% to 42.10. On Monday, shares hit a record high in intraday action of 42.29. Arrowhead stock broke out on Oct. 17, topping a buy point at 36.90 out of a cup base. Now, the stock is roughly 14% extended. CAN SLIM rules for investing suggest taking some profits when a stock rises 20%-25% above its buy point.
Vision Tech: Several Gene Therapies for Blindness Reach Clinical Trials
ProQR Therapeutics is a Netherlands-based company currently researching RNA therapies to inhibit or counteract the harmful effects of the defective genes associated with the above retinal diseases. How does that work? As you may recall from biology class, genes are the building blocks for the proteins that build and maintain our bodies.
Robotic Microscope Helping Surgeons During Delicate Brain Tumor Removal Procedures
There is amazing new technology that’s helping surgeons perform the most delicate of all operations — brain surgery. It saved the life of a Westchester County teenager whose headaches were from a brain tumor, CBS2’s Dr. Max Gomez reported Tuesday.
How Synaptive Medical is Transforming Neurosurgery
Neurosurgery is often thought of as one of the most difficult medical disciplines to pursue. Surgeons are tasked with breaching the multiple protective layers of the brain then navigating through an intricate web of fibers, tissues, blood vessels and fluid to extract a tumor or implant a device — all this without harming the delicate structures within.
Cell and Gene Therapies Necessitate New Lot Release Test Methods
Product-release testing is required for all drug products to ensure their quality and safety. For most conventional small-molecule and biologic drugs, batches are held until the release testing results are received and confirm the product is within specifications. Cell and gene therapies and some of their components (e.g., viral vectors), however, often must be used in further processing or administered to the patient within a short timeframe.
This Biotech Stock With A 221% Gain In 2019 Is Ready For ‘Prime Time’
Arrowhead Pharmaceuticals (ARWR) is using a technology called RNAi to tackle two colossal hurdles in treating genetic diseases. And it’s helping Arrowhead stock to finally realize profits after the biotech company operated for years in the red. RNAi, or RNA interference, is a method of silencing genes. Some genetic diseases cause the overproduction of troublesome proteins.
What Makes A Biopharma Serial Entrepreneur Tick? Part 1
Biopharmaceutical executives, especially those who have founded their own companies, never cease to amaze me. Why? Well for starters, the process of starting with nothing but an idea and then pulling together all the necessary resources to build a company capable of developing and delivering a product to patients is an amazing logistical challenge. It requires someone capable of big-picture thinking. Someone confident in being able to recruit top talent to join them on their journey.
